In recent years， the incidence of idiopathic pulmonary fibrosis in patients with lung cancer increased year by year. However， the diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer （IPF-LC） is difficult because of the lack of specific clinical manifestations， hematological and imaging features. IPF-LC patients often can not tolerate chemotherapy due to poor pulmonary function and other reasons， so the treatment options are limited. On the other hand，radiotherapy, chemotherapy and targeted treatment will increase the process of pulmonary fibrosis， leading to the treatment difficulties and poor prognosis. This study aims to summarize the epidemiology， pathogenesis， clinical features and treatment of IPF-LC.

Objective To observe the effects and adverse reactions of bevacizumab in brain metastases patients with serious cerebral edema. Methods

Retrospective analysis of 14 cases of brain metastasis patients with serious cerebral edema， including 7 cases of breast cancer， 5 cases of lung cancer， 1

case of esophagus cancer and 1 case of adenoid cystic carcinoma. Mannitol， dexamethasone and other conventional treatment were not effective in these patients. The symptom， quality of life and the volume of edema in T2 weighted MRI images before and after the bevacizumab treatment were compared. The adverse reactions were recorded in detail. Results The medium dose of bevacizumab was 4.76 mg/kg. The symptoms of 11 cases of brain metastases were significantly relieved after the bevacizumab treatment. Brain MRI indicated that the edema volumes before and after the treatment were reduced significantly［（38 804±14 859）mm3 vs.（80 100±28 338）mm3，P=0.02］. The edema index had a reduced trend（15.38±7.12 vs. 26.40±16.52，P＞0.05）. Adverse reactions associated with bevacizumab included bleeding in the nasal cavity and death in 1 patient， and hypertension in 3 patient. There were no proteinuria， anemia， stomatitis and other complications. Conclusion Bevacizumab has significant efficacy for treating serious cerebral edema， but patients should be selected carefully before receiving bevacizumab to avoid serious adverse reactions.

Objective  To summarize the clinicopathological characteristics， diagnosis and therapy as well as the prognostic factors of patients with thymic squamous cell carcinoma （TSCC）. Methods Twenty-four patients with TSCC admitted to Beijing Chest Hospital from January 2006 to April 2013 were retrospectively analyzed. Among them， 15 cases received surgical treatment （10 cases of combined radiotherapy and chemotherapy after operation， 3 cases of chemotherapy after operation， 1 case of radiotherapy after operation and 1 case without adjuvant treatment after operation） and 9 cases received palliative radiotherapy and chemotherapy. The clinical data of TSCC patients were analyzed. Follow-up data were collected and survival analysis was performed by Kaplan-Meier method. Results All patients were followed up for 1.0 to 139.0 months with a median follow-up time of 53.2 months. The overall survival （OS） was 2.5-139.0 months with a median OS of 68.1 months. The 1-， 3- and 5-year survival rates were 70.8％， 54.2％ and 41.7％， respectively. Kaplan-Meier univariate analysis indicated that Masaoka stage （P=0.018）， surgical resection （P=0.016） and surgical resection integrity （P=0.017） were the prognostic factors of TSCC patients. Postoperative radiotherapy did not prolong the patients’ prognosis （P=0.401）. Conclusion The clinical manifestation of TSCC is lack of specificity. Surgery is the main treatment. Masaoka stage and surgery have an impact on the prognosis of patients. Radical surgery has a better prognosis than palliative surgery. Postoperative radiotherapy has not been able to benefit patients’ survival. Clinical treatment should be formulated according to the physical condition of patients and the integrity of tumor resection.